PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884032
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884032
Cephalosporin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of cephalosporin Market
The global cephalosporin market continues to witness strong momentum, driven by increasing antimicrobial resistance, new product approvals, and rising demand for broad-spectrum antibiotics. In 2024, the market was valued at USD 7.93 billion, supported by high utilization of third- and fourth-generation cephalosporins for treating respiratory infections, skin infections, meningitis, and hospital-acquired bacterial diseases. The market is projected to grow to USD 8.32 billion in 2025, reflecting expanding usage across hospitals and outpatient settings. By 2032, the global market is expected to reach USD 12.07 billion, driven by increased AMR cases, accelerated approvals for advanced formulations, and investments in next-generation antibiotic research.
In 2024, North America dominated the market with a 46.78% share, owing to high infection prevalence, robust hospital infrastructure, and strong adoption of new cephalosporin drugs.
Market Drivers
A key driver shaping market growth is the escalating prevalence of antibiotic-resistant bacteria, which has increased demand for new-generation cephalosporins. Pharmaceutical companies such as GSK plc., Pfizer Inc., Sandoz Group AG, and Merck & Co., Inc., are intensifying R&D efforts to introduce innovative therapies capable of combating AMR strains. New approvals such as Basilea Pharmaceutica's ZEVTERA, approved by the U.S. FDA in April 2024, further strengthen market expansion by offering treatment options for bacteremia, ABSSSI, and pneumonia across adult and pediatric populations.
Cephalosporins offer fewer side effects, broad-spectrum coverage, and high therapeutic efficacy-features that continue to make them essential in global infectious disease management.
Market Restraints
Despite rising demand, the market faces challenges due to adverse reactions associated with cephalosporin use. Gastrointestinal problems, allergic reactions, and more severe neurotoxic effects have been reported, especially in older adults and those receiving high IV doses. In 2023, the New Zealand MARC highlighted risks including encephalopathy, seizures, and myoclonus associated with intravenous cephalosporins. These concerns may limit prescriptions in at-risk groups, thereby restraining market growth.
Market Opportunities
The emergence of nanoparticle-based drug delivery systems offers significant future potential. Research shows that gold nanoparticles (AuNPs) and silver nanoparticle-based formulations can revive and enhance the potency of older cephalosporin molecules. These nano-antibiotics improve drug efficacy, extend plasma half-life, and offer controlled drug release. Studies published by the NIH in 2023 demonstrated successful conversion of low-efficacy cephalosporins into potent nano-therapeutics, presenting lucrative opportunities for pharmaceutical innovations.
Segmental Analysis
By Generation
The third-generation cephalosporins dominated the market in 2024 due to their ability to treat meningitis, respiratory infections, and various soft-tissue infections. First-generation cephalosporins remain widely used for uncomplicated infections, while second-generation drugs maintain steady demand for respiratory and ENT infections. Meanwhile, fourth and fifth generations address rising AMR challenges and continue to gain traction.
By Route of Administration
The oral route is expected to record strong growth, supported by patient preference for self-administration and new drug approvals such as Fairdeal Corporation's Cefixime 400 mg tablets in 2024.
The parenteral route remains equally crucial, especially for severe infections requiring hospital-based treatments. New IV product launches, including Shionogi's Fetroja in 2023, strengthen this segment.
By Disease Indication
The urinary tract infections (UTI) segment is expected to dominate due to rising incidence of hospital-acquired UTIs and proven effectiveness of various cephalosporin generations in UTI management.
Other major segments-skin & soft tissue infections, respiratory infections, meningitis-also contribute significantly due to high global prevalence and broad clinical applications.
By Distribution Channel
Hospital pharmacies lead the market owing to high prescription volumes and treatment of acute infections requiring cephalosporins. Retail pharmacies follow, supported by wide accessibility and availability of oral formulations. Online pharmacies are growing steadily due to convenience, cost benefits, and increasing digital health adoption.
Regional Outlook
North America
North America generated USD 3.71 billion in 2024, supported by rising MRSA infections, high healthcare spending, and rapid adoption of advanced cephalosporin therapies. The U.S. leads the regional market, backed by continuous R&D investments-such as Roche's USD 50 billion expansion in 2025.
Europe
Europe holds the second-largest share, driven by increased consumption of second- and third-generation cephalosporins and strong antimicrobial stewardship initiatives.
Asia Pacific
The region is projected to witness the fastest CAGR between 2025 and 2032 due to large antibiotic consumption, robust API manufacturing, and strategic acquisitions such as Hasten Biopharmaceutics' 2023 purchase of Rocephin rights in China.
Latin America & Middle East/Africa
These regions show steady growth supported by increasing awareness of AMR, improving healthcare infrastructure, and new regulatory approvals for cephalosporin manufacturing.
Conclusion
Growing from USD 7.93 billion in 2024 to USD 12.07 billion by 2032, the global cephalosporin market is set for robust expansion. Rising AMR cases, advanced product launches, nano-antibiotic innovations, and strong government initiatives will continue to drive long-term demand across all major regions.
Segmentation
By Generation
- First Generation
- Second Generation
- Third Generation
- Fourth Generation
- Others
By Route of Administration
- Oral
- Parenteral
By Disease Indications
- Urinary Tract Infections
- Skin & Soft Tissue infection
- Respiratory Infections
- Meningitis
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- U.S.
- Canada
- Europe (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Pipeline Analysis, By Key Players
- 4.2. Overview of Antimicrobial Treatment Guidelines
- 4.3. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.5. New Product Launches, By Key Players
5. Global Cephalosporin Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Generation
- 5.1.1. First Generation
- 5.1.2. Second Generation
- 5.1.3. Third Generation
- 5.1.4. Fourth Generation
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Disease Indication
- 5.3.1. Urinary Tract Infections
- 5.3.2. Skin & Soft Tissue Infections
- 5.3.3. Respiratory Infections
- 5.3.4. Meningitis
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Cephalosporin Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Generation
- 6.1.1. First Generation
- 6.1.2. Second Generation
- 6.1.3. Third Generation
- 6.1.4. Fourth Generation
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Disease Indication
- 6.3.1. Urinary Tract Infections
- 6.3.2. Skin & Soft Tissue Infections
- 6.3.3. Respiratory Infections
- 6.3.4. Meningitis
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cephalosporin Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Generation
- 7.1.1. First Generation
- 7.1.2. Second Generation
- 7.1.3. Third Generation
- 7.1.4. Fourth Generation
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Disease Indication
- 7.3.1. Urinary Tract Infections
- 7.3.2. Skin & Soft Tissue Infections
- 7.3.3. Respiratory Infections
- 7.3.4. Meningitis
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Cephalosporin Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Generation
- 8.1.1. First Generation
- 8.1.2. Second Generation
- 8.1.3. Third Generation
- 8.1.4. Fourth Generation
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Disease Indication
- 8.3.1. Urinary Tract Infections
- 8.3.2. Skin & Soft Tissue Infections
- 8.3.3. Respiratory Infections
- 8.3.4. Meningitis
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Cephalosporin Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Generation
- 9.1.1. First Generation
- 9.1.2. Second Generation
- 9.1.3. Third Generation
- 9.1.4. Fourth Generation
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Disease Indication
- 9.3.1. Urinary Tract Infections
- 9.3.2. Skin & Soft Tissue Infections
- 9.3.3. Respiratory Infections
- 9.3.4. Meningitis
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Cephalosporin Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Generation
- 10.1.1. First Generation
- 10.1.2. Second Generation
- 10.1.3. Third Generation
- 10.1.4. Fourth Generation
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Disease Indication
- 10.3.1. Urinary Tract Infections
- 10.3.2. Skin & Soft Tissue Infections
- 10.3.3. Respiratory Infections
- 10.3.4. Meningitis
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Pfizer Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sandoz Group AG
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.,
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. AbbVie Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Bayer AG
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Astellas Pharma Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Shionogi & Co., Ltd
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Abbott
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.1. Pfizer Inc.
List of Tables
- Table 1: Global Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 2: Global Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 3: Global Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
- Table 4: Global Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 5: Global Cephalosporin Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 6: North America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 7: North America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 8: North America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
- Table 9: North America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 10: North America Cephalosporin Market Revenue (USD billion) Forecast, by Country, 2019-2032
- Table 11: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 12: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 13: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
- Table 14: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 15: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
- Table 16: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 17: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 18: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
- Table 19: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 20: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
- Table 21: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 22: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 23: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
- Table 24: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 25: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
- Table 26: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 27: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 28: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032
- Table 29: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 30: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2019-2032
List of Figures
- Figure 1: Global Cephalosporin Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Cephalosporin Market Value Share (%), by Generation, 2024 & 2032
- Figure 3: Global Cephalosporin Market Value Share (%), by Route of Administration, 2024 & 2032
- Figure 4: Global Cephalosporin Market Value Share (%), by Disease Indication, 2024 & 2032
- Figure 5: Global Cephalosporin Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 6: Global Cephalosporin Market Value Share (%), by Region, 2024 & 2032
- Figure 7: North America Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
- Figure 8: North America Cephalosporin Market Value Share (%), by Generation, 2024
- Figure 9: North America Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 10: North America Cephalosporin Market Value Share (%), by Route of Administration, 2024
- Figure 11: North America Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
- Figure 12: North America Cephalosporin Market Value Share (%), by Disease Indication, 2024
- Figure 13: North America Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 14: North America Cephalosporin Market Value Share (%), by Distribution Channel, 2024
- Figure 15: North America Cephalosporin Market Value (USD billion), by Country, 2024 & 2032
- Figure 16: North America Cephalosporin Market Value Share (%), by Country, 2024
- Figure 17: Europe Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
- Figure 18: Europe Cephalosporin Market Value Share (%), by Generation, 2024
- Figure 19: Europe Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 20: Europe Cephalosporin Market Value Share (%), by Route of Administration, 2024
- Figure 21: Europe Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
- Figure 22: Europe Cephalosporin Market Value Share (%), by Disease Indication, 2024
- Figure 23: Europe Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 24: Europe Cephalosporin Market Value Share (%), by Distribution Channel, 2024
- Figure 25: Europe Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
- Figure 26: Europe Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
- Figure 27: Asia Pacific Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
- Figure 28: Asia Pacific Cephalosporin Market Value Share (%), by Generation, 2024
- Figure 29: Asia Pacific Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 30: Asia Pacific Cephalosporin Market Value Share (%), by Route of Administration, 2024
- Figure 31: Asia Pacific Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
- Figure 32: Asia Pacific Cephalosporin Market Value Share (%), by Disease Indication, 2024
- Figure 33: Asia Pacific Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Cephalosporin Market Value Share (%), by Distribution Channel, 2024
- Figure 35: Asia Pacific Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
- Figure 36: Asia Pacific Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
- Figure 37: Latin America Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
- Figure 38: Latin America Cephalosporin Market Value Share (%), by Generation, 2024
- Figure 39: Latin America Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 40: Latin America Cephalosporin Market Value Share (%), by Route of Administration, 2024
- Figure 41: Latin America Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
- Figure 42: Latin America Cephalosporin Market Value Share (%), by Disease Indication, 2024
- Figure 43: Latin America Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 44: Latin America Cephalosporin Market Value Share (%), by Distribution Channel, 2024
- Figure 45: Latin America Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
- Figure 46: Latin America Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
- Figure 47: Middle East & Africa Cephalosporin Market Value (USD billion), by Generation, 2024 & 2032
- Figure 48: Middle East & Africa Cephalosporin Market Value Share (%), by Generation, 2024
- Figure 49: Middle East & Africa Cephalosporin Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 50: Middle East & Africa Cephalosporin Market Value Share (%), by Route of Administration, 2024
- Figure 51: Middle East & Africa Cephalosporin Market Value (USD billion), by Disease Indication, 2024 & 2032
- Figure 52: Middle East & Africa Cephalosporin Market Value Share (%), by Disease Indication, 2024
- Figure 53: Middle East & Africa Cephalosporin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Cephalosporin Market Value Share (%), by Distribution Channel, 2024
- Figure 55: Middle East & Africa Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2024 & 2032
- Figure 56: Middle East & Africa Cephalosporin Market Value Share (%), by Country/Sub-Region, 2024
- Figure 57: Global Cephalosporin Market Share (%), by Company, 2024
